A pharmacokinetic/pharmacodynamic analysis of intravenous tranexamic acid in adult patients undergoing elective total hip arthroplasty (ORACLE)
British Journal of Anaesthesia · 2026-04 · 136 (4) · 1157-1165
DOI: 10.1016/j.bja.2024.12.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Anaesthesia, 2026-04. Verfasst von Usha Gurunathan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesia and Perfusion Services, The Prince Charles Hospital, Brisbane, QLD, Australia; Faculty of Medicine, The University of Queen…. Hauptthemen laut MEDLINE: Tranexamic Acid, Arthroplasty, Replacement, Hip, Antifibrinolytic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Metro North Hospital and Health Service, National Health and Medical Research Council.
Abstract (Originalsprache)
BACKGROUND: Uncertainty about optimal tranexamic acid (TXA) dosage has led to significant practice variation in hip arthroplasty. We aimed to identify the optimal intravenous dosage of TXA using a population pharmacokinetic/pharmacodynamic (PK/PD) approach in adults undergoing primary elective hip arthroplasty. METHODS: Participants received an i.v. TXA bolus dose of 15 mg kg-1 of total body weight, 30 min before skin incision (maximum dose 1500 mg). Blood samples were collected at baseline, 5 min post-TXA, skin incision, skin closure, and 3, 6, and 24 h post-TXA administration. TXA activity was measured ex vivo using a tissue plasminogen activator-induced clot lysis assay, targeted to achieve 90% maximal antifibrinolysis, based on maximum lysis rate. A nonlinear mixed-effects population PK/PD model was developed. Monte Carlo simulations (n=1000) identified the dosing regimens to achieve the PK/PD target over 24 h. RESULTS: There were 24 participants (18 females, 6 males), with a median (range) age of 62 (56.5-72) yr and BMI of 31.1 (23.0-41.8) kg m-2. A three-compartment model best described the 24-h data. The 15 mg kg-1 i.v. bolus maintained TXA concentrations above the PK/PD target of 10 mg L-1 for a median duration of 4.94 h (IQR: 3.76-8.21 h). Of the various simulated regimens, only 30 mg kg-1 i.v. TXA infusion after this bolus achieved the 24-h PK/PD target in 76-100% of patients, varying with their estimated glomerular function rates. CONCLUSIONS: The PK/PD modelling indicated that a 15 mg kg-1 i.v. TXA bolus followed by a continuous i.v. infusion achieved the 24-h antifibrinolytic target. CLINICAL TRIAL REGISTRATION: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377339&isClinicalTrial=False (ACTRN12619000670178); registered on May 6, 2019.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesia and Perfusion Services, The Prince Charles Hospital, Brisbane, QLD, Australia; Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. Electronic address: usha.gurunathan@h…
- Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
- Department of Anaesthesia and Perfusion Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
- University of Queensland Centre for Clinical Research, Brisbane, QLD, Australia.
- University of Queensland Centre for Clinical Research, Brisbane, QLD, Australia; Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; Herston Infectious Dis…
- Department of Anaesthesia and Perfusion Services, The Prince Charles Hospital, Brisbane, QLD, Australia; Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Förderung
- Metro North Hospital and Health Service
- National Health and Medical Research Council
Zitieren
APA
Gurunathan, U., Medcalf, R. L., Chiang, L., Liu, Z., Liu, X., Keragala, C. B., Hernandez-Mitre, M. P., Brady, P., Wallis, S. C., Roberts, J. A., Mullany, D., Nandurkar, H., Eley, V., & Parker, S. L. (2026). A pharmacokinetic/pharmacodynamic analysis of intravenous tranexamic acid in adult patients undergoing elective total hip arthroplasty (ORACLE). British Journal of Anaesthesia, 136(4), 1157-1165. https://doi.org/10.1016/j.bja.2024.12.004
Vancouver
Gurunathan U, Medcalf RL, Chiang L, Liu Z, Liu X, Keragala CB, et al. A pharmacokinetic/pharmacodynamic analysis of intravenous tranexamic acid in adult patients undergoing elective total hip arthroplasty (ORACLE). British Journal of Anaesthesia. 2026;136(4):1157-1165. doi:10.1016/j.bja.2024.12.004
BibTeX
@article{Gurunathan2026,
author = {Gurunathan, Usha and Medcalf, Robert L and Chiang, Lily and Liu, Zikou and Liu, Xin and Keragala, Charithani B and Hernandez-Mitre, Maria Patricia and Brady, Paul and Wallis, Steven C and Roberts, Jason A and Mullany, Daniel and Nandurkar, Harshal and Eley, Victoria and Parker, Suzanne L},
title = {A pharmacokinetic/pharmacodynamic analysis of intravenous tranexamic acid in adult patients undergoing elective total hip arthroplasty (ORACLE)},
journal = {British Journal of Anaesthesia},
year = {2026},
volume = {136},
number = {4},
pages = {1157--1165},
doi = {10.1016/j.bja.2024.12.004}
}
EUVIMED